Brown Advisory
SGMO

Brown Advisory’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Brown Advisory’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-19,147
Closed -$33.7K – 1242
2023
Q1 		$33.7K Buy
19,147
+2,507
+15% +$7.16K ﹤0.01% 1194
2022
Q4 		$52.3K Buy
16,640
+3,500
+27% +$13.6K ﹤0.01% 1182
2022
Q3 		$64K Sell
13,140
-5,639
-30% -$29K ﹤0.01% 1109
2022
Q2 		$78K Buy
18,779
+6,176
+49% +$26.7K ﹤0.01% 1079
2022
Q1 		$73K Buy
12,603
+2,489
+25% +$14.8K ﹤0.01% 1092
2021
Q4 		$76K Buy
+10,114
New +$87.9K ﹤0.01% 1217

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory's SGMO Position: Q2 2023 in Review

Brown Advisory sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 19,147 shares — an estimated $33.7K sold.

Brown Advisory first reported a position in SGMO in Q4 2021 and held it in 6 quarters. The position peaked at $78K in Q2 2022. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • Brown Advisory reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • Brown Advisory sold 19,147 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $33.7K.
  • Brown Advisory first reported a position in SANGAMO THERAPEUTICS INC in Q4 2021 and held it in 6 quarters.
  • Brown Advisory's SANGAMO THERAPEUTICS INC position peaked at $78K in Q2 2022.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Brown Advisory's 13F filing for Q2 2023, filed 31 Jul 2023.